Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 16/20 | 0.54 |
| ▸ | GPR55 | Q9Y2T6 | 4/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4939243 | 0.84 | SLC6A9 (0.57) | SLC6A9GPR55CNR1TSHR | |
| SCHEMBL4934622 | 0.83 | SLC6A9 (0.56) | SLC6A9GPR55CNR1TSHR | |
| SCHEMBL4936345 | 0.83 | SLC6A9 (0.65) | SLC6A9GPR55KCNH2TSHR | |
| SCHEMBL14028685 | 0.83 | SLC6A9 (0.56) | SLC6A9GPR55CNR1TSHR | |
| SCHEMBL4948280 | 0.80 | SLC6A9 (0.68) | SLC6A9GPR55CNR1TSHR | |
| SCHEMBL4943081 | 0.79 | SLC6A9 (0.57) | SLC6A9GPR55CNR1 | |
| SCHEMBL4937577 | 0.79 | SLC6A9 (0.71) | SLC6A9GPR55TSHR | |
| SCHEMBL4434158 | 0.77 | SLC6A9 (0.80) | SLC6A9GPR55CNR1TSHR | |
| SCHEMBL4943129 | 0.76 | SLC6A9 (0.67) | SLC6A9GPR55KCNH2TSHR | |
| SCHEMBL4424927 | 0.75 | SLC6A9 (0.74) | SLC6A9GPR55CNR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | SLC1A1, SLC6A7, SLC1A2 | SLC6A9 9/4885GPR55 485/4885CNR1 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.